Exozymes (NASDAQ:EXOZ - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.22) EPS for the quarter, Zacks reports.
Exozymes Stock Performance
Shares of NASDAQ EXOZ traded up $0.51 during midday trading on Monday, reaching $13.52. 34,989 shares of the company's stock were exchanged, compared to its average volume of 19,536. Exozymes has a 52-week low of $8.50 and a 52-week high of $23.99. The stock's fifty day moving average price is $12.14.
Exozymes Company Profile
(
Get Free Report)
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exozymes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exozymes wasn't on the list.
While Exozymes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
